The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness
Introduction: When Coronavirus Disease-19 (COVID-19) struck the world in December 2019, initiatives started to investigate the efficacy of convalescent plasma, a readily available source of passive antibodies, collected from recovered patients as a therapeutic option. This was based on historical ob...
Main Authors: | So-Osman, C, Burnouf, T, Al-Riyami, AZ, Bloch, EM, Estcourt, L, Goel, R, Tiberghien, P, Vermeulen, M, Wendel, S, Wood, EM |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Frontiers Media
2024
|
Similar Items
-
Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2
by: Valk, SJ, et al.
Published: (2021) -
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
by: Piechotta, V, et al.
Published: (2021) -
Hyperimmune immunoglobulin for people with COVID-19
by: Kimber, C, et al.
Published: (2021) -
Clinical use of convalescent plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities
by: Al-Riyami, AZ, et al.
Published: (2020) -
How should we use convalescent plasma therapies for the management of COVID-19?
by: Wood, EM, et al.
Published: (2020)